Octapharma aiming to gain hold in Australia's plasma market

11/2/2009 | Age (Melbourne, Australia), The

Octapharma Australia's proposal two years ago to establish a $400 million plasma fractionation plant in the country has yet to get support from the federal government, despite being backed by the Queensland government. The proposed plant would pose a challenge to the monopoly held by CSL, the company that currently fractionates all the blood products in the country. "Any request for access to Australian plasma" must be reviewed by the federal-state health ministers' conference responsible for the country's blood-supply agreement, according to the federal Health Department.

View Full Article in:

Age (Melbourne, Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI